Manifold appoints former execs from Kyruus Health, Health Catalyst and more digital health hires

Manifold, an AI-enabled clinical research platform, announced five new appointments to its leadership team and two new members of its advisory team. 

Chris McMahon joins the company as chief people officer, Alex Akersd as vice president of growth, Danielle Kowalski as vice president of legal, Megan Ahigian as senior director of product and partnerships and Taylor Gleason as senior director of marketing. 

McMahon, Ahigian and Gleason previously held similar roles at Kyruus Health, Akers served as VP of sales at Health Catalyst and Kowalski was VP and deputy general counsel of HubSpot’s legal and compliance function. 

Mike Longo and Chris Reisig will join the company as go-to-market advisors. Longo previously worked as Veeva’s vice president of research and development in North America. 

“We’re thrilled to welcome some of the industry’s strongest leaders to help us transform clinical study and data operations with our AI-powered platform,” said Vinay Seth Mohta, CEO and Co-Founder of Manifold. “Our team will be crucial to growing our partnerships and expanding our solutions – achieving our vision of making it ten times faster and one-tenth the cost to carry out modern studies and analytics.” 

Healthcare data company ConcertAI announced Dhiraj Carumbay has been appointed senior vice president and general manager of the company’s TeraRecon business. 

Carumbay managed business units at RadNet, Amazon AWS, Philips Healthcare, Fujifilm, and GE HealthCare. At AWS, he oversaw Amazon’s cloud solutions for the healthcare and life sciences industries. Prior to that, he held business leadership and global product roles at GE HealthCare. 

“Dhiraj started his career focused on diagnostic imaging and directly running healthcare provider solutions using AI – that was the key criterion we had for this leadership role,” Jeff Elton, CEO of ConcertAI, said in a statement. 

“His depth in imaging broadly, SaaS technologies, and AI, he is uniquely suited to ensure our provider and biopharma partners have the most advanced technologies and data to transform the diagnostic and research experience.”